REPLIGEN CORP Convertible Notes Payable
REPLIGEN CORP (RGEN) had Convertible Notes Payable of $240.94 million as of 2020-09-30, per its 10-Q filed 2020-11-05.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleNotesPayable · last filed 2020-11-05
- 2020-09-30: Convertible Notes Payable $240.94M.
- 2020-06-30: Convertible Notes Payable $238.18M.
- 2020-03-31: Convertible Notes Payable $235.46M.
- 2019-12-31: Convertible Notes Payable $232.77M.
| Period end | Convertible Notes Payable |
|---|---|
| 2020-09-30 | $240.94M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $238.18M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $235.46M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $232.77M 10-Q · filed 2020-11-05 |
| 2019-09-30 | $230.18M 10-Q · filed 2019-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |